Skip to content
  • CAREERS
  • RFP

MLM ONLINE ®

Search
MLM Medical Labs
  • Meet MLM
    • About
    • Leadership
    • Global Reach Without Compromise
    • Quality / Accreditations & Certifications
    • MLM News and Insights
  • Services
    • Preclinical
      • Preclinical Services Overview
      • Cell Culture Modeling
      • In-Vivo Models
        • Fibrosis Models
    • Specialty Testing and Translational
      • Assay Development and Validation
      • Harmonized Flow Cytometry
      • Biomarkers in Neurodegeneration Disease Detection
      • Cell & Gene Therapy and ATMP Services
      • Animal Nutritional Developmental Studies
      • Medical Device Support
    • Histology
      • Immunostaining IHC/IF
      • Digital Pathology
      • Histology Image Gallery
    • Central lab services
      • Central Lab Overview
      • Safety Lab Testing
      • Study Set Up
      • Sample Analysis
      • MLM Kit Building®
      • mlm online®
      • Data Management
      • Global Logistics
    • MLM Kit Building®
      • MLM Kit Building®
      • MLM Safeguard Box®
    • Sample processing and Management
      • Global Access to High-Quality PBMCs
      • Point of Collection Tracking
  • Analytical Overview
    • Immunoassays
    • Platelet Function Assays
    • Multiplex Assays
    • Enzymatic Assays
    • Coagulation
    • Flow Cytometry
    • RT-PCR
    • HPLC
    • CELL-BASED Assays
    • Histology
  • Assay Menu
  • Resources
    • Knowledge Library
    • Unit Converter
    • Histology Image Gallery
  • Contact
    • Contact Us
    • Request For Proposals
    • Your Feedback
    • Subscribe
    • Locations
  • CAREERS
  • RFP

MLM ONLINE ®

Search
MLM Medical Labs
  • Meet MLM
    • About
    • Leadership
    • Global Reach Without Compromise
    • Quality / Accreditations & Certifications
    • MLM News and Insights
  • Services
    • Preclinical
      • Preclinical Services Overview
      • Cell Culture Modeling
      • In-Vivo Models
        • Fibrosis Models
    • Specialty Testing and Translational
      • Assay Development and Validation
      • Harmonized Flow Cytometry
      • Biomarkers in Neurodegeneration Disease Detection
      • Cell & Gene Therapy and ATMP Services
      • Animal Nutritional Developmental Studies
      • Medical Device Support
    • Histology
      • Immunostaining IHC/IF
      • Digital Pathology
      • Histology Image Gallery
    • Central lab services
      • Central Lab Overview
      • Safety Lab Testing
      • Study Set Up
      • Sample Analysis
      • MLM Kit Building®
      • mlm online®
      • Data Management
      • Global Logistics
    • MLM Kit Building®
      • MLM Kit Building®
      • MLM Safeguard Box®
    • Sample processing and Management
      • Global Access to High-Quality PBMCs
      • Point of Collection Tracking
  • Analytical Overview
    • Immunoassays
    • Platelet Function Assays
    • Multiplex Assays
    • Enzymatic Assays
    • Coagulation
    • Flow Cytometry
    • RT-PCR
    • HPLC
    • CELL-BASED Assays
    • Histology
  • Assay Menu
  • Resources
    • Knowledge Library
    • Unit Converter
    • Histology Image Gallery
  • Contact
    • Contact Us
    • Request For Proposals
    • Your Feedback
    • Subscribe
    • Locations

Clinical Insights

Metabolic Dysfunction in Nonalcoholic Steatohepatitis (NASH) – MASH More Fitting Term

Unraveling the Connection: Metabolic Dysfunction in Nonalcoholic Steatohepatitis (NASH) – MASH Determined to be a More Fitting Term

by Katie Dineen, B.S. Biology, Business Development Manager, Preclinical Research Lab

Introduction: 

Nonalcoholic Steatohepatitis (NASH) is a progressive liver disease characterized by inflammation and liver cell damage. One crucial aspect contributing to the development and progression of NASH is metabolic dysfunction.  

Understanding NASH: 

NASH falls under the broader category of nonalcoholic fatty liver disease (NAFLD), where excessive fat accumulates in the liver without alcohol consumption being the primary cause. What sets NASH apart is the presence of inflammation and liver cell injury, leading to severe complications like cirrhosis and liver failure.  

Metabolic Dysfunction as a Key Player: 

Metabolic dysfunction refers to a range of abnormalities in the body’s metabolic processes, including insulin resistance, obesity, and dyslipidemia. These dysfunctions are closely intertwined with the development and progression of NASH.  

  1. Insulin Resistance: 
    – Insulin resistance is a hallmark of metabolic dysfunction in NASH.  
    – The liver becomes less responsive to insulin, leading to increased glucose production and storage as fat.
    – Elevated insulin levels contribute to fat accumulation in the liver, a key factor in NASH pathogenesis.

  2. Obesity:
    – Obesity is a major risk factor for both metabolic dysfunction and NASH. 
    – Adipose tissue secretes inflammatory molecules, promoting liver inflammation in NASH patients.
    – The excess fat in the body exacerbates insulin resistance, creating a vicious cycle that accelerates liver damage.
      
  3. Dyslipidemia:
    – Dyslipidemia, characterized by abnormal levels of cholesterol and triglycerides, is common in individuals with metabolic dysfunction and NASH. 
    – Imbalances in lipid metabolism contribute to the accumulation of fat in the liver and exacerbate inflammation.  
The Interplay of Factors: 

The relationship between metabolic dysfunction and NASH involves a cascade of events that contribute to liver injury and inflammation. Metabolic dysfunction not only promotes the initial accumulation of fat in the liver but also creates an inflammatory environment that sustains and exacerbates liver damage over time.  

Is MASH More Appropriate Terminology? 

There has been a growing discussion in the medical community about the appropriateness of the term “NASH,” considering its strong association with metabolic factors. Some experts have suggested that “Metabolic Associated Steatohepatitis” (MASH) might be a more accurate descriptor, emphasizing the central role of metabolic dysfunction in the disease’s etiology.  

Clinical Implications: 

Understanding the role of metabolic dysfunction in NASH (or MASH) has important clinical implications. Targeting metabolic abnormalities through lifestyle modifications, weight loss, and pharmacological interventions is a key strategy in managing NASH. Addressing insulin resistance and obesity can help break the cycle of liver damage and inflammation, potentially slowing or even reversing the progression of this liver disease.  

Conclusion: 

Metabolic dysfunction plays a pivotal role in the complex landscape of NASH. Recognizing the interconnections between insulin resistance, obesity, and dyslipidemia is crucial for developing effective strategies to manage and treat this progressive liver disease. As the debate over terminology continues, addressing metabolic dysfunction emerges as a promising avenue for improving patient outcomes and preventing the long-term complications associated with this challenging condition.  

Share this:

Facebook
X
LinkedIn
All Categories
Brochures
Clinical Insights
News and Events
Press Releases
Scientific Publications
Videos

Related Posts

CD4/CD8 Duplex Immunofluorescence : High-Resolution Immune Profiling from a Single Slide

Read now »

Targeting the IRE1α-XBP1 Axis: A Novel Approach in ALI Treatment

Read now »

Managing PBMC Complexity in Global Immuno-Oncology Trials

Read now »

Power Your Oncology & Immunology Trials with AI-Enhanced Histopathology

Read now »

MLM Medical Labs – Germany Awarded 6th Consecutive CAP Accreditation for Service Excellence

Read now »
Subscribe to mlm newsletter

Share this:

Post navigation
← Previous Post
Next Post →

© 2025 MLM Medical Labs

  • Editorial Information
  • Privacy Policy
Subscribe to mlm newsletter